The PeptideCores Retatrutide research pen delivers independently HPLC verified Retatrutide — the first triple GLP-1R/GIPR/GCGR receptor co-agonist to reach Phase 3 research stages — in a pre-filled pen injector format delivering 4 x 1mg research doses. Each pen contains 4mg of Retatrutide at 99%+ purity with a batch-specific COA from an independent third-party laboratory. For laboratory research use only.
Triple Receptor Mechanism
GLP-1R: Insulin secretion, glucagon suppression, appetite signalling. GIPR: Incretin amplification, adipose tissue metabolism. GCGR: Hepatic glucose output, energy expenditure, lipolysis — effects exclusive to triple agonism not achievable with mono or dual agonists.
Product Specifications
| Specification | Detail |
|---|---|
| Format | Pre-filled research pen injector |
| Total quantity | 4mg Retatrutide |
| Dose per click | 1mg |
| Number of doses | 4 doses |
| Receptor targets | GLP-1R / GIPR / GCGR triple agonist |
| Purity | 99%+ HPLC verified — independent |
| Molecular weight | ~4759.4 g/mol |
| COA | Batch-specific — independent lab |
| Storage sealed | -20C |
| Storage in use | 4C — use within 28 days |
| Shipping | EU-wide — dispatched within 24hrs |
For laboratory research purposes only. Not for human or veterinary use.




Reviews
There are no reviews yet.